...
首页> 外文期刊>Acta Poloniae Pharmaceutica: Durg Research >Matrix type transdermal therapeutic system containing captopril: Formulation optimization, in vitro and ex vivo characterization
【24h】

Matrix type transdermal therapeutic system containing captopril: Formulation optimization, in vitro and ex vivo characterization

机译:含有卡托普利的基质型透皮治疗系统:配方优化,体外和离体表征

获取原文
获取原文并翻译 | 示例
           

摘要

Transdermal therapeutic systems (TTS) containing captopril were developed by using synthetic and pH independent polymers, Eudragit RL 100 and RS 100. The formulations were characterized in terms of their appearance, thickness, captopril content, in vitro release rate and diffusion profiles. In vitro release studies demonstrated controlled release for each formulation developed. In vitro and ex vivo diffusion rate studies were performed through various synthetic membranes with different thickness, pore size and type (hydrophilic and hydrophobic) and through human skin by using Franz diffusion cells. Type of membrane and composition of the formulation affected the diffusion profiles of captopril from the transdermal therapeutic systems. Transdermal therapeutic systems containing captopril were successfully prepared and especially two of the formulations (F15 and F16) are considered to be suitable to administer captopril via skin.
机译:含有卡托普利的透皮治疗系统(TTS)是通过使用合成的和pH无关的聚合物Eudragit RL 100和RS 100开发的。制剂的外观,厚度,卡托普利含量,体外释放速率和扩散曲线均经过了表征。体外释放研究表明,所开发的每种制剂均具有控制释放。体外和离体扩散速率研究是通过使用不同厚度,孔径和类型(亲水性和疏水性)的各种合成膜以及使用Franz扩散池的人皮肤进行的。膜的类型和制剂的组成影响了卡托普利从透皮治疗系统的扩散情况。已成功制备了含有卡托普利的透皮治疗系统,尤其是其中两种制剂(F15和F16)被认为适合于通过皮肤施用卡托普利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号